CACHEXIA

This early-phase study tests a new DNA-based medicine called SXRN in 28 people with advanced solid tumors who have not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if it can improve appetite and physical function. …

This study tests a new form of the drug megestrol acetate (nanocrystalline) to help cervical cancer patients avoid severe weight loss and muscle wasting during chemoradiotherapy. About 88 women with advanced cervical cancer will either receive the drug plus standard treatment or …

This early-stage trial tests a drug called AV-380 in 30 adults with advanced cancer who are losing weight and muscle (cachexia) and have high levels of a protein called GDF-15. The drug is given alongside standard chemotherapy to see if it is safe and how the body processes it. T…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This study looks at genetic differences in people with pancreatic cancer to understand why many develop severe muscle wasting (cachexia). Researchers will collect blood samples from 100 patients and track weight loss over three months. The goal is to find genetic markers that cou…

This study looks at muscle wasting, weight loss, and tiredness in people with stomach, pancreas, or bowel cancer who are having surgery. Researchers will track changes in body composition, physical activity, and quality of life over a year. The goal is to better understand cachex…

This study aims to make sure lab tests, equipment, and procedures used in research on obesity, diabetes, heart disease, and bone disorders are accurate and give consistent results. It will involve up to 100 healthy volunteers and people with these conditions, aged 18 to 100. The …